海外の治験の状況「1」での検索結果
8300件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
- Pancreatic Cancer
- Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom, United States
- 2016-09-30
Recruiting
- Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- United States
- 2017-12-18
Recruiting
- A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer
- Small Cell Lung Cancer
- China
- 2017-12-15
Recruiting
- RESIST-2: 2nd-line ART for HIV-2 Infection
- HIV-2 Infection
- Senegal
- 2017-12-14
Recruiting
- Clinical study of Apatinib combined with docetaxel as second-line treatment in advanced gastric cancer
- gastric cancer
- China
- 2017-12-11
Recruiting
- The Combination Chemotherapy of SIRIOX as First-Line Chemotherapy for Pancreatic Cancer
- Carcinoma, Pancreatic Ductal
- China
- 2017-11-28
Recruiting
- Lifestyle On-line Intervention in Patients With Obesity and Hypertension
- Obesity;Hypertension;Obesity;Hypertension;Obesity;Hypertension
- Spain
- 2018-01-05
Recruiting
- Phase II trial of docetaxel plus ramucirumab combination therapy in patients with advanced EGFR gene mutation positive advanced stage non-squamous cell nonsmall cell lung cancer (HSR 1701)
- non-small cell lung cancer
- Japan
- 2018-01-04
Recruiting
- The Japanese T2D study for evaluating Benefits Of a New first-line therapy with Dapagliflozin in consideration of improving QOL (J-BOND study)
- type 2 diabetes mellitus
- Japan
- 2018-01-01
Recruiting
- A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
- Biliary Tract Cancer
- United States
- 2018-12-25
Recruiting
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
- Australia, Belgium, China, Czechia, France, Germany, Italy, Japan, Korea, Republic of, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2018-12-18
Recruiting
- Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
- Advanced Melanoma
- Australia, Canada, Spain, Sweden, United States
- 2018-12-13
Recruiting
- A single-arm phase II study for Anlotinib plus Docetaxel as a second-line therapy in patients with advanced non-small-cell lung cancer
- lung cancer;C34.900
- China
- 2018-12-11
Recruiting
- 1565nm non-ablative fractional laser in the treatment of periorbital fine lines: a prospective, self-controlled clinical trial
- periorbital fine lines
- China
- 2018-11-28
Recruiting
- Phase II trial, multicenter, first line Paclitaxel-Avelumab Treatment for inoperable Angiosarcoma
- ;Neoplasms
- Korea, Republic of
- 2018-11-09
Recruiting
- Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Gastric, or Gastroesophageal Junction Adenocarcinoma
- China, France, Italy, Korea, Republic of, Poland, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, Turkey, United States
- 2018-11-09
Recruiting
- Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
- Non Small Cell Lung Cancer
- China
- 2018-11-08
Recruiting
- A Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS).
- Leukemia, Myeloid, Chronic-Phase
- Germany
- 2018-11-07
Recruiting
- The Effect of Early Versus Standard Central Line Removal on Growth of Very Low Birth Weight Premature Infants
- Growth Failure;CLABSI - Central Line Associated Bloodstream Infection
- Poland
- 2018-11-01
Recruiting
- Phase II study of pembrolizumab in advanced hepatocellular carcinoma as second-line treatment after failure of sorafenib: integration of genomic analysis to identify predictive molecular subtypes
- ;Neoplasms
- Korea, Republic of
- 2018-10-25